Vascular Specialist–August 2023


In this issue:

  • SVS responds to New York Times exposé on overuse of vascular interventions 
  • Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
  • Vascular surgery added as named specialty to influential national hospital rankings
  • Guest Editorial: Adam Tanious, MD, ruminates on how to navigate industry rep exchanges 
  • uTBAD: A new randomized trial aimed at improving the lives of aortic dissection patients 



Please enter your comment!
Please enter your name here